Data Updates in GI Cancers and HCC from ESMO 2024 - Episode 1

5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC

,

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.

Now Viewing
EP. 1: 5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC
EP. 2: The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC
EP. 3: Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial
EP. 4: Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
EP. 5: Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
EP. 6: Building Upon Approved Combination Regimens in Unresectable HCC
EP. 7: Ongoing Research in GI Cancers

Related Content:

Gastrointestinal CancerHepatocellular Carcinoma
Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC
FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer
Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers